Setanaxib
Small molecule
Also known as GKT137831
Evidence outlook
Primary Biliary Cholangitis: topline reported 2024-07-26
The sponsor reported topline results on 2024-07-26 (Phase 2b TRANSFORM of setanaxib in PBC met its primary endpoint (ALP reduction versus placebo)). The announcement is listed under Regulatory events.
Latest reported trial: TRANSFORM (NCT05014672) · Phase 2 · met primary endpoint · grade pending
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
TRANSFORM NCT05014672 · Primary Biliary Cholangitis Registry: NCT05014672 | 2 | Change in ALP at Week 24 Compared to Baseline (Baseline (Day 1) and Week 24) 2024-05-31 | Primary endpoint, change in ALP vs placebo: statistically significant improvement for both doses (Calliditas topline, 2024-07-26). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Primary Biliary Cholangitis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Setanaxib: this drug | Phase 2 | Small molecule | NOX1/4 | not yet graded | No reviewed efficacy summary in this indication | |
| Elafibranor (Iqirvo) | Approved | Small molecule | PPAR-alpha/PPAR-delta | Partial signal | NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8) | |
| Seladelpar (Livdelzi) | Approved | Small molecule | PPAR-delta | Partial signal | NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02). NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results). | |
| Saroglitazar (Lipaglyn) | Phase 3 | Small molecule | PPAR-alpha/PPAR-gamma | Partial signal | NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29). | |
| Pemafibrate (Parmodia) | Phase 2 | Small molecule | PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Volixibat | Phase 2 | Small molecule | Ileal bile acid transporter (IBAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent